Single cell Raman spectroscopic profiles predict treatment responses in patients with de novo acute myeloid leukemia
Frontiers in Cell and Developmental Biology · 28.04.2026 · 14
DOI: 10.3389/fcell.2026.1767226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 28.04.2026. Verfasst von Ming Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Hospital of Jilin University, Changchun, China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Leukemia is a clonal malignant proliferative disease originating from hematopoietic stem cells. Although its treatment strategy has gradually developed from traditional chemotherapy to a multimodal treatment system including novel targeted therapy and immunotherapy, primary drug resistance in particular remains the core clinical problem leading to poor patient prognosis. This clinical dilemma indicates that the traditional genotyping system based on genomics has not been able to fully resolve the molecular heterogeneity of acute myeloid leukemia (AML), and it is urgent to establish a precise stratified model that can dynamically reflect the functional status of tumor cells in the initial stage of treatment.
Methods
In this study, Raman spectroscopy (RS) combined with machine learning algorithm was used to construct a metabolic prognosis prediction model for AML chemotherapy response. Bone marrow single cell Raman spectroscopy data of newly diagnosed AML patients were collected, and the molecular fingerprint was analyzed by principal component analysis linear discriminant analysis (PCA-LDA) and multivariate curve resolute alternating least square method (MCR-ALS).
Results
The results showed that the PCALDA model achieved complete remission or non-remission (CR/NR) classification through 24 principal components (cumulative variance contribution of 90.1%), the accuracy of external validation was 94.8% (sensitivity 97.9%, specificity 92.0%), and the AUC reached 96.27%. Protein, lipid, nucleic acid and mixed components were decomposed by MCR-ALS, and lipid and nucleic acid metabolic pathways were enriched in NR group (P < 0.001).
Discussion
Studies have shown that RS single-cell metabolic fingerprint can decode the metabolic reprogramming features associated with chemotherapy resistance in AML, providing a new marker-free and highly sensitive tool for real-time prognostic stratification and targeted intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Hospital of Jilin University, Changchun, China.
- Key Laboratory of Hematology Precision Medicine of Jilin Province, The First Hospital of Jilin University, Changchun, China.
- Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences, Changchun, China.
Zitieren
APA
Zhang, M., Su, L., Han, W., Song, F., Fu, Y., Chi, M. B., Chen, X., Wu, Y. H., & Gao, S. J. (2026). Single cell Raman spectroscopic profiles predict treatment responses in patients with de novo acute myeloid leukemia. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1767226
Vancouver
Zhang M, Su L, Han W, Song F, Fu Y, Chi MB, et al. Single cell Raman spectroscopic profiles predict treatment responses in patients with de novo acute myeloid leukemia. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1767226
BibTeX
@article{Zhang2026,
author = {Zhang, Ming and Su, Long and Han, Wei and Song, Fei and Fu, Yu and Chi, Ming-Bo and Chen, Xing and Wu, Yi-Hui and Gao, Su-Jun},
title = {Single cell Raman spectroscopic profiles predict treatment responses in patients with de novo acute myeloid leukemia},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1767226}
}
EUVIMED